BioCryst Partners With Shionogi On Influenza Antiviral In Japan
This article was originally published in PharmAsia News
Executive Summary
BioCryst Pharmaceuticals and Shionogi & Company have signed an agreement giving the Japanese drug maker an exclusive license to develop and commercialize the Birmingham, Ala., company's Phase II influenza antiviral peramivir in Japan, the companies announced March 5
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)